| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2020 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 000 | 2 | NIH | 10/23/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $300,000 ) |
| | 2023 | 2023 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R43MH133248 | Induction of bnAbs against HIV-1 gp41. | 001 | 2 | NIH | 8/22/2023 | $300,000 |
| | 2023 | 2022 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R43MH133248 | Induction of bnAbs against HIV-1 gp41. | 000 | 1 | NIH | 10/18/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $297,312 ) |
| | 2022 | 2022 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R43MH133248 | Induction of bnAbs against HIV-1 gp41. | 000 | 1 | NIH | 9/1/2022 | $297,312 |
| | 2022 | 2020 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 000 | 2 | NIH | 11/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $69,562 ) |
| | 2021 | 2020 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 001 | 2 | NIH | 5/5/2021 | $40,449 |
| | 2021 | 2019 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 000 | 1 | NIH | 5/5/2021 | $29,113 |
|
| Issue Date FY: 2020 ( Subtotal = $210,000 ) |
| | 2020 | 2020 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 000 | 2 | NIH | 12/6/2019 | $210,000 |
|
| Issue Date FY: 2019 ( Subtotal = $175,000 ) |
| | 2019 | 2019 | NEOVAXSYN INC | 4140 COCHRANE PKWY | AMES | IA | 50014-7725 | STORY | USA | R21AI143505 | Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy | 000 | 1 | NIH | 12/18/2018 | $175,000 |
|
|
